吉利德科学携两款亚洲首发展品亮相进博会

新京报2025-11-07

在第八届中国国际进口博览会（以下简称进博会）上，吉利德科学携多款产品亮相，其中包括两款亚洲首发产品：长效HIV暴露前预防药物Lenacapavir（来那帕韦）和原发性胆汁性胆管炎（PBC）新药Seladelpar，以及在华上市的13款创新药物等。　　来那帕韦是全球同类首创、一年仅需给药两次的长效HIV衣壳抑制剂，针对用于HIV暴露前预防的全球Ⅲ期临床研究证明，来那帕韦预防HIV的有效性超过...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2581079810?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-07 19:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581079810","market":"hk","top_or_hot":-1,"title":"吉利德科学携两款亚洲首发展品亮相进博会","media":"新京报","content":"<div>\n<p>在第八届中国国际进口博览会（以下简称进博会）上，吉利德科学携多款产品亮相，其中包括两款亚洲首发产品：长效HIV暴露前预防药物Lenacapavir（来那帕韦）和原发性胆汁性胆管炎（PBC）新药Seladelpar，以及在华上市的13款创新药物等。　　来那帕韦是全球同类首创、一年仅需给药两次的长效HIV衣壳抑制剂，针对用于HIV暴露前预防的全球Ⅲ期临床研究证明，来那帕韦预防HIV的有效性超过...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202511073558461893.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德科学携两款亚洲首发展品亮相进博会</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德科学携两款亚洲首发展品亮相进博会\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-07 19:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202511073558461893.html><strong>新京报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>在第八届中国国际进口博览会（以下简称进博会）上，吉利德科学携多款产品亮相，其中包括两款亚洲首发产品：长效HIV暴露前预防药物Lenacapavir（来那帕韦）和原发性胆汁性胆管炎（PBC）新药Seladelpar，以及在华上市的13款创新药物等。　　来那帕韦是全球同类首创、一年仅需给药两次的长效HIV衣壳抑制剂，针对用于HIV暴露前预防的全球Ⅲ期临床研究证明，来那帕韦预防HIV的有效性超过...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202511073558461893.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739699.SGD","symbol_name":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202511073558461893.html","article_id":"2581079810","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511073558461893.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2581079810","pubTimestamp":1762516799,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"在第八届中国国际进口博览会（以下简称进博会）上，吉利德科学携多款产品亮相，其中包括两款亚洲首发产品：长效HIV暴露前预防药物Lenacapavir（来那帕韦）和原发性胆汁性胆管炎（PBC）新药Seladelpar，以及在华上市的13款创新药物等。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4585":"ETF&股票定投概念","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4139":"生物科技","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4566":"资本集团","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4578":"CAR-T","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","GILD":"吉利德科学","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4550":"红杉资本持仓","BK4588":"碎股","BK4568":"美国抗疫概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","SG9999015978.USD":"利安颠覆性创新基金A","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4583":"猴痘概念","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4532":"文艺复兴科技持仓","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC"},"translate_title":"Gilead Sciences debuts in China International Import Expo with two Asian debut exhibits","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1.5},"content_text":"在第八届中国国际进口博览会（以下简称进博会）上，吉利德科学携多款产品亮相，其中包括两款亚洲首发产品：长效HIV暴露前预防药物Lenacapavir（来那帕韦）和原发性胆汁性胆管炎（PBC）新药Seladelpar，以及在华上市的13款创新药物等。　　来那帕韦是全球同类首创、一年仅需给药两次的长效HIV衣壳抑制剂，针对用于HIV暴露前预防的全球Ⅲ期临床研究证明，来那帕韦预防HIV的有效性超过99.9%。凭借在HIV预防领域的突破，来那帕韦荣获《科学》杂志“2024年度十大科学突破”榜首，入选美国《时代》周刊“2025最佳发明”榜单，并于近日摘得素有“医药界诺贝尔奖”之称的2025年盖伦奖“最佳医药产品奖”。今年6月底，来那帕韦在海南博鳌乐城国际医疗旅游先行区获批用于HIV暴露前预防，与美国食品药品监督管理局（FDA）获批仅隔数日，开创了国内先行区获批几乎同步与美国FDA获批的先例。　　展出的另一款药物Seladelpar是针对原发性胆汁性胆管炎患者的创新药物。原发性胆汁性胆管炎是一种慢性自身免疫性肝病，是易被忽视的肝脏“隐形杀手”，于2023年被纳入国家卫健委发布的《第二批罕见病》目录。除疾病进展风险外，瘙痒是PBC患者最常见的症状之一，对生活质量产生显著影响。Seladelpar作为全球首个既能改善PBC患者生化指标、又可缓解瘙痒症状的创新疗法，于今年8月依托北京临床急需进口政策，在北京天竺罕见病药品保障先行区获批。　　进入中国八年多来，吉利德科学已在国内上市13款全球创新药物，累计惠及约180万中国患者。此次进博会上，吉利德科学还深化与各方合作，就提升创新药物可及、推动规范诊疗等方面计划签署近十项合作项目。（文章来源：新京报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581079810","isCrawlerRequest":true}